Cerebrolysin

Cerebrolysin is not a single peptide but rather a complex mixture of over 100 different low-molecular-weight peptides and free amino acids derived from pig brain tissue. Developed in Austria in 1949, it is one of the oldest and most extensively studied neuroprotective compounds in clinical medicine. The peptide fragments in Cerebrolysin mimic the activity of your brain's own growth and repair molecules, including BDNF, NGF, GDNF, and CNTF. These are the signaling proteins your brain naturally uses to grow new neurons, repair damaged ones, and maintain healthy connections between brain cells.

Cerebrolysin is approved as a prescription medication in over 45 countries across Europe, Asia, and Russia for treating stroke recovery, traumatic brain injury, dementia, and Alzheimer's disease. It is manufactured by EVER Neuro Pharma in Austria and is considered a standard of care for neurological conditions in many countries. However, it is not FDA approved in the United States, and some large clinical trials have produced mixed results, particularly for acute stroke treatment. The strongest evidence supports its use for Alzheimer's disease and as a complement to rehabilitation after stroke or brain injury.

What sets Cerebrolysin apart from single-peptide nootropics like Semax or Selank is its multi-target approach. Instead of boosting one growth factor or modulating one neurotransmitter system, Cerebrolysin provides a broad cocktail of neurotrophic support that mimics the natural repair response your brain would mount on its own. Its small molecular weight (under 10 kilodaltons) allows it to cross the blood-brain barrier, which is critical because natural neurotrophic factors are too large to make this crossing and cannot reach the brain when administered as drugs.

Imagine your brain has its own repair crew that gets dispatched whenever neurons are damaged or stressed. This crew includes growth factors like BDNF (which helps neurons grow and strengthen connections), NGF (which keeps neurons alive), GDNF (which protects dopamine-producing neurons), and CNTF (which supports the cells that insulate your neural wiring). Cerebrolysin essentially provides reinforcements for this repair crew. Its peptide fragments mimic the effects of all these growth factors simultaneously, stimulating the same cellular repair and growth processes they normally trigger. One clinical trial found it increased serum BDNF levels by 300% over 16 weeks, and when combined with donepezil (an Alzheimer's medication), BDNF increased by a remarkable 600%.

On the protective side, Cerebrolysin shields neurons from multiple types of damage. It reduces excitotoxicity (what happens when too much glutamate overstimulates and kills neurons), blocks the formation of harmful free radicals, calms down overactive immune cells in the brain (microglia), and prevents neurons from triggering their self-destruct sequence (apoptosis). These mechanisms are especially important after stroke or brain injury, when a cascade of secondary damage can kill far more neurons than the initial event. Cerebrolysin also supports neuroplasticity by promoting new synapse formation, increasing dendritic branching, and encouraging axonal sprouting, all of which help the brain rewire around damaged areas.

Perhaps most remarkably, research shows Cerebrolysin can stimulate neurogenesis, the birth of entirely new neurons from stem cells already present in your brain. It promotes the proliferation, maturation, and migration of neural progenitor cells, which may contribute to recovery after injury and could slow decline in neurodegenerative diseases. In Alzheimer's models, it has been shown to decrease amyloid beta production by altering how amyloid precursor protein gets processed. The overall effect is a compound that supports virtually every aspect of brain health: protection, repair, new growth, and the clearance of toxic proteins.